No fungal vaccine has ever been approved for human use. This isn’t for lack of need: invasive fungal infections kill an estimated 2.5 million people every year, a toll that rivals tuberculosis. The reasons we lack fungal vaccines come down to a collision of biology, immunology, and economics that makes fungi uniquely difficult targets.
Fungi Are Too Similar to Human Cells
Bacteria are fundamentally different from human cells. Viruses are barely cells at all. But fungi are eukaryotes, just like us. They share the same basic cellular architecture: membrane-bound nuclei, similar protein-building machinery, and overlapping metabolic pathways. Genomic studies have found that nearly 1,000 human proteins have closer equivalents in the fungal kingdom than in flies or worms. This genetic closeness is the root of the problem.
When you design a vaccine against a bacterium or virus, you’re targeting structures that look nothing like anything in the human body. With fungi, the molecular targets you’d want to attack often resemble human molecules closely enough that distinguishing “foreign invader” from “self” becomes far harder. This same challenge plagues antifungal drugs, which is why we have relatively few of those compared to antibiotics. The closer an organism is to us genetically, the narrower the window for safe, selective targeting.
Fungal Immunity Requires a Different Kind of Response
Most successful vaccines work by training your immune system to produce antibodies, proteins that recognize and neutralize a specific invader. This approach works brilliantly for viruses and many bacteria. Fungi, however, don’t cooperate with this strategy.
Protection against fungal infections depends heavily on T cells, a different arm of the immune system. Specifically, two types of T cell responses are critical. Th1 cells produce signaling molecules that activate the immune cells capable of engulfing and destroying fungal invaders. Th17 cells recruit neutrophils, a type of white blood cell that directly kills fungal organisms, and promote the release of natural antimicrobial compounds. The strongest antifungal protection comes from activating both of these responses simultaneously.
Building a vaccine that reliably triggers this coordinated T cell response is significantly more complex than designing one that generates antibodies. Some fungi make the problem worse with their own defenses. Cryptococcus neoformans, for instance, surrounds itself with a polysaccharide capsule that actively suppresses the protective Th1 response and resists being engulfed by immune cells. It’s essentially wearing molecular armor that also jams the immune system’s radar.
The People Who Need It Most Can’t Respond to It
Healthy immune systems generally handle fungal exposure without trouble. You inhale fungal spores constantly, and your body clears them before they cause disease. The people who develop life-threatening fungal infections are overwhelmingly those with weakened immune systems: cancer patients undergoing chemotherapy, organ transplant recipients on immunosuppressive drugs, people with untreated HIV, or those born with immune deficiencies.
This creates a painful paradox. The patients who most desperately need a fungal vaccine are precisely the ones least able to mount a strong immune response to one. A vaccine tested in healthy volunteers might look promising, then fail in the immunocompromised patients it was designed to protect. Their weakened T cell responses, the very responses a fungal vaccine depends on, mean the vaccine may simply not “take.” No other major category of infectious disease has its primary target population so fundamentally at odds with vaccine mechanics.
There Are Hundreds of Fungal Species, Not Just One
A single fungal vaccine would need to cover an enormous range of threats. The WHO’s fungal priority pathogens list places four species in the critical category: Candida albicans, Aspergillus fumigatus, Candida auris, and Cryptococcus neoformans. Each of these organisms has different surface structures, different infection strategies, and different ways of evading immunity. Beyond these, Histoplasma species, Mucorales (the cause of mucormycosis), Coccidioides, and Pneumocystis all cause serious disease.
The numbers are staggering. Over 2.1 million people develop invasive aspergillosis annually, with a mortality rate of 85%. Candida bloodstream infections affect 1.6 million people, killing nearly 64% of them. Cryptococcal meningitis kills over 75% of the 194,000 people it infects each year. Each of these pathogens would ideally need its own vaccine, multiplying the research, trials, and investment required.
Researchers are exploring whether components of the fungal cell wall could serve as universal targets. Beta-glucans, sugar polymers found in the walls of most fungi, are the most promising candidate. A “pan-fungal” vaccine linking a beta-glucan called laminarin to a carrier protein has shown protection against both Candida and Aspergillus in animal models and entered early clinical trials. Other groups are working with mannans and chitin, additional cell wall sugars, though these tend to need extra immune-boosting agents to generate a strong response.
The Money Isn’t There
Pharmaceutical companies have been reluctant to invest in fungal vaccines, primarily because the profit margins are low. The populations most affected by invasive fungal disease are concentrated in low-income settings or among patients already consuming enormous healthcare resources. Fungal infections are sometimes called “neglected” for good reason: they lack the public visibility and advocacy infrastructure that drove rapid vaccine development for diseases like HPV or COVID-19.
Limited funding compounds every other challenge. The biological hurdles are solvable in principle, but solving them requires sustained investment in clinical trials that are expensive and slow. Without external backing from governments or global health organizations, the financial case for fungal vaccine development remains weak compared to viral or bacterial targets with larger, more commercially attractive markets.
Where Candidates Stand Now
Despite all these barriers, a handful of vaccine candidates have reached human trials. NDV-3A, which targets a protein found on the surface of Candida, completed a Phase 1/2 trial for preventing recurrent vaginal yeast infections. The trial design assumed a 50% vaccine efficacy, a modest goal that reflects how early this field remains. Another candidate called PEV7 has also advanced to late-stage trials. Neither has received FDA approval.
Some of the most tangible progress is happening in veterinary medicine. A live-attenuated vaccine for Valley fever (caused by Coccidioides) has shown strong promise in dogs, with preliminary data indicating that a prime-and-booster regimen provides a high level of immunity against natural infection. Researchers at the University of Arizona are working with the USDA toward licensing, with large-scale canine safety studies in progress. A successful dog vaccine could serve as proof of concept and accelerate the path toward a human version.
The field is also shifting its approach to adjuvants and delivery systems. Because fungal vaccines need to drive T cell responses rather than just antibody production, conventional vaccine formulations often fall short. Newer strategies pair fungal antigens with specific immune-stimulating compounds designed to push the immune system toward Th1 and Th17 activation, essentially reprogramming the type of response the vaccine generates.
The gap between the severity of fungal disease and the tools available to prevent it is one of the largest in modern medicine. Closing it will require not just scientific breakthroughs but a shift in how the world prioritizes and funds this category of infection.